

DTOS Re PCT/PTO 1-4 DEC 2004

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/501,402
Filing Date	July 15, 2004
First Named Inventor	Jensen-Jarolim
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	37488.00400US

Total Number of Pages in This Submission

**ENCLOSURES (Check all that apply)**

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form                                | <input type="checkbox"/> Drawing(s)                                       | <input type="checkbox"/> After Allowance communication to Group                            |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Licensing-related Papers                         | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences        |
| <input type="checkbox"/> Amendment/Reply                                     | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information   |
| <input type="checkbox"/> Affidavits/declaration(s)                           | <input type="checkbox"/> Power of Attorney, Revocation                    | <input type="checkbox"/> Status Letter   |
| <input type="checkbox"/> Extension of Time Request                           | <input type="checkbox"/> Change of Correspondence Address                 | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):            |
| <input type="checkbox"/> Express Abandonment Request                         | <input type="checkbox"/> Terminal Disclaimer                              |  |
| <input checked="" type="checkbox"/> Information Disclosure Statement         | <input type="checkbox"/> Request for Refund                               |  |
| <input type="checkbox"/> Certified Copy of Priority Document(s)              | <input type="checkbox"/> CD, Number of CD(s) _____                        |  |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application    |   |  |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 |   |  |

Remarks

1. Copies of 8 Cited References

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Einar Stole, Reg. No. 47,272
Signature	<i>Einar Stole</i>
Date	December 14, 2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Signature

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ATTORNEY DOCKET NO. 37488.00400US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Jensen-Jarolim, <i>et al.</i>	)	Group Art Unit: Not Yet Assigned
	)	
US Application Serial No. 10/501,402	)	
	)	
Filed: July 15, 2004	)	Examiner: Not Yet Assigned
	)	
For: <i>Oral Vaccination</i>	)	

**MAIL STOP DD**

Commissioner of Patents  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in C.F.R. § 1.56, applicants are submitting herewith copies of references listed on the attached Form PTO/SB/08B for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO/SB/08B with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

Applicants' submission of the Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.


In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted before the mailing of a First Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in any event any fee is deemed necessary,

the Commissioner is authorized to charge the undersigned's Deposit Account No. 13-3250 under reference No. 37488.00400US.


Respectfully submitted,

**MILBANK, TWEED, HADLEY & McCLOY LLP**

Date: December 14, 2004

By:   
Einar Stole  
Registration No. 47,272

**Customer No. 38647**  
**MILBANK, TWEED, HADLEY & McCLOY LLP**  
1825 I Street, N.W., Suite 1100  
Washington, DC 20006  
Tel. No. (202) 835-7500  
Fax No. (202) 835-7586



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/501,402
Filing Date	July 15, 2004
First Named Inventor	Jensen-Jarolim
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	37488.00400US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		"Anaphylaxis to Russian Beluga Caviar," Letters to the Editor, XP008018087	
		Tam, James P., "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system," Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 5409-5413, August 1988	
		Nagy et al., "Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus," Cancer Immunology Immunother (1991) 34: 63-69	
		Neuchrist, C., "Distribution of Immunoglobulins in Squamous Cell Carcinoma of the Head and Neck," Int Arch Allergy Immunol 1994; 104: 97-100	
		Kershaw, Michael H. et al., "Tumor-Specific IgE-Mediated Inhibition of Human Colorectal Carcinoma Xenograft Growth," Oncology Research, Vol. 10, pp. 133-142, 1998	
		Olszewaska, Wieslawa, et al., "Protection against Measles Virus-Induced Encephatitis by Anti-mimotope Antibodies: The Role of Antibody Affinity," Virology 272, 98-105 (2000)	
		Reali, Eva, et al., "IgEs Targeted on Tumor Cells: Therapeutic Activity and Potential in the Design of Tumor Vaccines," Cancer Research 61, 5517-5522, July 15, 2001	
		Swoboda, Ines, "Recombinant Carp Parvalbumin, the Major Cross-Reactive Fish Allergen: A Tool for Diagnosis and Therapy of Fish Allergy," The Journal of Immunology, pp. 4576-4584 (2000)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.